###begin article-title 0
###xml 96 97 92 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn1">*</xref>
###xml 97 99 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn2">S&#8414;</xref>
Polo-like Kinase 2 (PLK2) Phosphorylates alpha-Synuclein at Serine 129 in Central Nervous System*Sâƒž
###end article-title 0
###begin p 1
Present address: National Center for Preparedness, Detection, and Control of Infectious Diseases (NCPDCID), Coordinating Center for Infectious Disease, Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, Bldg. 1, Rm. 118, MS-C21, Atlanta, GA 30333.
###end p 1
###begin p 2
Present address: ActiveSite Pharmaceuticals, Inc., 187 Magellan Ave., San Francisco, CA 94416.
###end p 2
###begin p 3
###xml 151 175 151 175 <email xmlns:xlink="http://www.w3.org/1999/xlink">john.p.anderson@elan.com</email>
 To whom correspondence should be addressed: Elan Pharmaceuticals, Inc., 800 Gateway Blvd., South San Francisco, CA, 94080. Fax: 650-553-7196; E-mail: john.p.anderson@elan.com. 
###end p 3
###begin p 4
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice
###end p 4
###begin p 5
 applies to Author Choice Articles
###end p 5
###begin p 6
###xml 540 548 528 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 694 701 678 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 823 827 807 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink">plk2</italic>
###xml 682 687 <span type="species:ncbi:10090">mouse</span>
Several neurological diseases, including Parkinson disease and dementia with Lewy bodies, are characterized by the accumulation of alpha-synuclein phosphorylated at Ser-129 (p-Ser-129). The kinase or kinases responsible for this phosphorylation have been the subject of intense investigation. Here we submit evidence that polo-like kinase 2 (PLK2, also known as serum-inducible kinase or SNK) is a principle contributor to alpha-synuclein phosphorylation at Ser-129 in neurons. PLK2 directly phosphorylates alpha-synuclein at Ser-129 in an in vitro biochemical assay. Inhibitors of PLK kinases inhibited alpha-synuclein phosphorylation both in primary cortical cell cultures and in mouse brain in vivo. Finally, specific knockdown of PLK2 expression by transduction with short hairpin RNA constructs or by knock-out of the plk2 gene reduced p-Ser-129 levels. These results indicate that PLK2 plays a critical role in alpha-synuclein phosphorylation in central nervous system.
###end p 6
###begin p 7
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice-Final version full access.
###end p 7
###begin p 8
###xml 0 19 0 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Note Added in Proof</italic>
###xml 343 417 335 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Parkinson's Disease, Molecular and Therapeutic Insights from Model Systems</italic>
###xml 123 128 <span type="species:ncbi:10090">mouse</span>
Note Added in Proof-Brit Mollenhauer and Michael G. Schlossmacher have recently identified PLK2 in a survey of proteins in mouse brain interacting with alpha-synuclein. Their chapter, "Purification and quantification of neural alpha-synuclein: Relevance for patho-genesis and biomarker development," is in Nass, R., and Przedborski, S. (2008) Parkinson's Disease, Molecular and Therapeutic Insights from Model Systems, Elsevier Academic Press Inc., Burlington, MA.
###end p 8
###begin p 9
###xml 141 154 141 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">advertisement</italic>
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 9
###begin p 10
The on-line version of this article (available at ) contains a supplemental figure, a supplemental table, and supplemental procedures.
###end p 10
###begin p 11
###xml 79 80 75 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn5">4</xref>
###xml 257 258 253 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 259 260 255 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref3">3</xref>
###xml 362 363 358 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref4">4</xref>
###xml 364 365 360 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 520 521 516 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref7">7</xref>
###xml 522 523 518 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
The importance of alpha-synuclein to the pathogenesis of Parkinson disease (PD)4 and the related disorder, dementia with Lewy bodies (DLB), is suggested by its association with Lewy bodies and Lewy neurites, the inclusions that characterize these diseases (1-3), and demonstrated by the existence of mutations that cause syndromes mimicking sporadic PD and DLB (4-6). Furthermore, three separate mutations cause early onset forms of PD and DLB. It is particularly telling that duplications or triplications of the gene (7-9), which increase levels of alpha-synuclein with no alteration in sequence, also cause PD or DLB.
###end p 11
###begin p 12
###xml 98 100 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 204 206 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 208 210 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 291 293 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 295 297 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 318 320 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 321 323 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 468 470 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
###xml 600 602 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 849 859 845 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 861 863 857 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
###xml 897 899 893 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 901 903 897 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref18">18</xref>
###xml 1124 1126 1116 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 1413 1415 1401 1403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 849 859 <span type="species:ncbi:7227">Drosophila</span>
###xml 883 888 <span type="species:ncbi:10090">mouse</span>
###xml 920 942 <span type="species:ncbi:272636">adeno-associated virus</span>
###xml 985 988 <span type="species:ncbi:10116">rat</span>
alpha-Synuclein has been reported to be phosphorylated on serine residues, at Ser-87 and Ser-129 (10), although to date only the Ser-129 phosphorylation has been identified in the central nervous system (11, 12). Phosphorylation at tyrosine residues has been observed by some investigators (13, 14) but not by others (10-12). Phosphorylation at Ser-129 (p-Ser-129) is of particular interest because the majority of synuclein in Lewy bodies contains this modification (15). In addition, p-Ser-129 was found to be the most extensive and consistent modification in a survey of synuclein in Lewy bodies (11). Results have been mixed from studies investigating the function of phosphorylation using S129A and S129D mutations to respectively block and mimic the modification. Although the phosphorylation mimic was associated with pathology in studies in Drosophila (16) and in transgenic mouse models (17, 18), studies using adeno-associated virus vectors to overexpress alpha-synuclein in rat substantia nigra found an exacerbation of pathology with the S129A mutation, whereas the S129D mutation was benign, if not protective (19). Interpretation of these studies is complicated by a recent study showing that the S129D and S129A mutations themselves have effects on the aggregation properties of alpha-synuclein independent of their effects on phosphorylation, with the S129A mutation stimulating fibril formation (20). Clearly, determination of the role of p-Ser-129 phosphorylation would be helped by identification of the responsible kinase. In addition, identification will provide a pathologically relevant way to increase phosphorylation in a cell or animal model.
###end p 12
###begin p 13
###xml 103 105 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 107 109 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 111 113 107 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 176 178 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 475 483 463 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 823 830 803 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 758 763 <span type="species:ncbi:10090">mouse</span>
Several kinases have been proposed to phosphorylate alpha-synuclein, including casein kinases 1 and 2 (10, 12, 21) and members of the G-protein-coupled receptor kinase family (22). In this report, we offer evidence that a member of the polo-like kinase (PLK) family, PLK2 (or serum-inducible kinase, SNK), functions as an alpha-synuclein kinase. The ability of PLK2 to directly phosphorylate alpha-synuclein at Ser-129 is established by overexpression in cell culture and by in vitro reaction with the purified kinase. We show that PLK2 phosphorylates alpha-synuclein in cells, including primary neuronal cultures, using a series of kinase inhibitors as well as inhibition of expression with RNA interference. In addition, inhibitor and knock-out studies in mouse brain support a role for PLK2 as an alpha-synuclein kinase in vivo.
###end p 13
###begin title 14
EXPERIMENTAL PROCEDURES
###end title 14
###begin p 15
###xml 0 13 0 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kinase Assays</italic>
###xml 213 215 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 334 336 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 525 526 509 510 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 560 561 540 541 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 572 573 552 553 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 734 735 714 715 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 755 756 735 736 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 766 767 746 747 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 892 893 872 873 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 913 914 893 894 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 924 925 904 905 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 947 948 927 928 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 959 960 939 940 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 965 966 945 946 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1071 1072 1045 1046 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1113 1114 1087 1088 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1172 1173 1146 1147 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1193 1194 1167 1168 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1203 1204 1177 1178 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1660 1661 1622 1623 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1765 1766 1727 1728 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 601 608 <span type="species:ncbi:3847">soybean</span>
###xml 794 800 <span type="species:ncbi:9913">bovine</span>
###xml 1216 1222 <span type="species:ncbi:9913">bovine</span>
Kinase Assays-To prepare biotinylated alpha-synuclein substrate, a cysteine residue was introduced into the C terminus (141C-alphaSyn) of the recombinant alpha-synuclein expression construct previously described (11), using site-directed mutagenesis (QuikChange XL, Stratagene), and the resulting alpha-synuclein mutant was prepared (11). The C-terminal cysteine was biotinylated with maleimide-polyethylene glycol 2-biotin (Pierce). PLK1, -2, -3, and -4 (Carna Biosciences) or CK 2 (New England Biolabs) were mixed with 66 nm biotin-141C-alpha-synuclein (33 nm) and 0.2 mm phospholipid vesicles (75% soybean phosphatidylcholine (Sigma Aldrich), 25% 1-palmitoyl-2-oleoyl-sre-glycero-3-phosphate (Avanti Polar Lipids) in buffer A (25 mm Hepes, pH 7.5, 50 mm NaCl, 2 mm dithiothreitol, 0.1 mg/ml bovine serum albumin). The kinase reaction was started by adding an equal volume of buffer B (25 mm Hepes, pH 7.5, 50 mm NaCl, 2 mm dithiothreitol, 0.2 mm ATP, 0.2 mm MgCl2) and incubated at 30 degreesC for 30 min. Europium cryptate-labeled p-Ser-129-specific11A5 antibody (2 nm) and streptavidin-allophycocyanin (7.5 nm) were added in the same reaction volume of buffer C (25 mm Hepes, pH 7.5, 0.8 m KF, 66 nm EDTA, 0.1% bovine serum albumin), and fluorescence intensity was measured. Uniform phosphorylation of the p-Ser-129 alpha-synuclein standard was confirmed by reverse phase-high pressure liquid chromatography and mass spectroscopy. The p-Ser-129 alpha-synuclein standard curve was obtained under the same conditions as for measurement of assay samples, without kinase. Unphosphorylated alpha-synuclein was added to keep the total synuclein constant at 33 nm. For inhibitor studies, compounds were serially diluted in buffer B, with a PLK2 concentration of 0.3 nm.
###end p 15
###begin p 16
###xml 0 47 0 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Targeted Gene Disruption and Generation of Plk2</italic>
###xml 47 48 47 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 48 49 48 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">/</sup>
###xml 48 49 48 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>/</sup></italic>
###xml 49 50 49 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 50 54 50 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mice</italic>
###xml 55 59 55 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">plk2</italic>
###xml 59 62 59 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;/&#8211;</sup>
###xml 110 114 110 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">plk2</italic>
###xml 166 170 166 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">plk2</italic>
###xml 391 395 391 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">plk2</italic>
###xml 704 706 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 718 722 718 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">plk2</italic>
###xml 722 725 722 725 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;/&#8211;</sup>
###xml 50 54 <span type="species:ncbi:10090">Mice</span>
###xml 63 67 <span type="species:ncbi:10090">mice</span>
###xml 593 597 <span type="species:ncbi:10090">mice</span>
###xml 762 766 <span type="species:ncbi:10090">Mice</span>
Targeted Gene Disruption and Generation of Plk2-/-Mice-plk2-/- mice were prepared by Caliper Life Sciences. A plk2 targeting construct was designed to replace all 14 plk2 exons (deletion between sequences 5'-CAGCCAGCCGGCGCGTATTTAAAGC-3' and 5'-AGCACGGGTTCCTGACACGTCAG-3') with a Neo cassette (targeting vector FtNwCD, Caliper Life Sciences). This targeting construct was used to disrupt the plk2 gene in C57BL6 embryonic stem cells. These embryonic stem cells were injected into blastocysts and implanted into pseudo-pregnant females. Resulting germ line chimeras were crossed to C57BL/6N Tac mice, and heterozygous offspring were intercrossed to produce PLK2-null animals. Similar to a previous report (23), few live plk2-/- homozygous offspring were observed. Mice were genotyped by PCR using the following primers: 5'-CTGTGCTCGACGTTGTCACTG-3' and 5'-GATCCCCTCAGAAGAACTCGT-3' for the disrupted allele and 5'-CTTGCTCGTACTCATCACGGCA-3' and 5'-AACCTAGTCACTTAGCAATGCCAGGT-3' for the wild-type allele.
###end p 16
###begin p 17
###xml 0 36 0 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Preparation of Lentiviral Constructs</italic>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
Preparation of Lentiviral Constructs-The lentiviral plasmid designated pAGMK was generated by modifying the parent lentiviral plasmid pCSC-SP-PW-GFP1 (24) as described in the supplemental materials. The cDNA coding for alpha-synuclein or alpha-synuclein (E46K) was cloned into pAGMK to replace green fluorescent protein, using the AgeI/PmeI sites. The Plk2 short hairpin RNA (shRNA) containing plasmid (TRCN0000000869, CCGGGTGACGGTGCTGAAATACTTTCTCGAGAAAGTATTTCAGCACCGTCACTTTTT) was obtained from Sigma. The procedures for lentivirus production are described in the supplemental materials. After the total RNA was isolated, the efficiency of mRNA knockdown by shRNA was determined by TaqMan quantitative RT-PCR with the Applied Biosystems Gene-Assay kit using the protocol provided by the supplier. The relative copy number of PLK2 mRNA in the cellular extract was calculated after normalization to a housekeeping mRNA, glyceraldehyde-3-phosphate dehydrogenase.
###end p 17
###begin p 18
###xml 0 42 0 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cortical Cultures from PLK2 Knock-out Mice</italic>
###xml 384 390 384 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 534 535 534 535 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 555 556 555 556 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 566 567 566 567 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 577 578 577 578 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 588 589 588 589 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 592 593 592 593 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 594 595 594 595 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 596 597 596 597 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 602 603 602 603 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 606 607 606 607 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 609 610 609 610 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 38 42 <span type="species:ncbi:10090">Mice</span>
###xml 129 133 <span type="species:ncbi:10090">mice</span>
Cortical Cultures from PLK2 Knock-out Mice-Embryonic day 15 embryos were obtained from heterozygous PLK2 knockout crossed C57Bl6 mice (International Animal Care and Use Convention (IACUC) protocol MO-PH-05-08). Each embryo was placed in a distinct Petri dish for subsequent genotyping analysis as described above. Cultures, at least 95% neuronal, were prepared as described by Wright et al. (25). After 14 days in culture, cells were washed in ice-cold phosphate-buffered saline and lysed in ice-cold cell extraction buffer (CEB; 10 mm Tris, pH 7.4, 100 mm NaCl, 1 mm EDTA, 1 mm NaF, 20 mm Na2P2O7, 2 mm Na3VO4, 1% Triton X-100, 10% glycerol, 0.1% SDS, 0.5% deoxycholate). Plates were snap-frozen on dry ice and stored at -80 degreesC. Duplicate plates from each culture were harvested for qRT-PCR as detailed below. RNA was extracted from samples and purified using the Qiagen RNeasy 96 kit according to the Qiagen protocol.
###end p 18
###begin p 19
###xml 0 28 0 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Transfection of HEK293 Cells</italic>
###xml 279 280 275 276 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 438 439 434 435 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 454 455 450 451 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 599 600 595 596 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 420 426 <span type="species:ncbi:9913">bovine</span>
Transfection of HEK293 Cells-HEK293 cells were co-transfected with pAGMK-alpha-synuclein (wild type), along with either pCMV6-XL4 empty vector or pCMV6-XL4 vector containing PLK2 (OriGene Technologies, Rockville, MD). Cells were plated at a density of 4,000 cells/well into poly-d-lysine-coated 96-well plates. The following day, growth medium was replaced with 293 medium (Dulbecco's modified Eagle's medium, 10% fetal bovine serum, 20 mm glutamine, 1 mm sodium pyruvate), and cDNAs were incubated at room temperature with Lipofectamine 2000 (Invitrogen) for 15 min prior to transfection with 100 nm siRNA and Lipofectamine 2000 per well following the manufacturer's instructions. Cells were washed in cold phosphate-buffered saline 48 h after transfection and then harvested in CEB. Plates were snap-frozen on dry ice and stored at -80 degreesC.
###end p 19
###begin p 20
###xml 0 85 0 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Compound Treatment of Swiss-Webster Cortical Cultures and of Transfected HEK293 Cells</italic>
###xml 450 451 450 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 474 475 474 475 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 499 500 499 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 571 572 571 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 86 91 <span type="species:ncbi:10090">Mouse</span>
Compound Treatment of Swiss-Webster Cortical Cultures and of Transfected HEK293 Cells-Mouse cortical cultures were prepared as described above from embryonic day 15 Swiss-Webster embryos, except that the embryonic cortices were pooled. Cells were maintained for 14 days prior to inhibitor treatment. Transfected HEK293 cells were prepared as described above. The following inhibitors were diluted into medium, and cells were treated for 2 h: BI2536, N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methylphenyl)urea (APMU), and 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT; Calbiochem). After 2 h, cells were washed and lysed as described above.
###end p 20
###begin p 21
###xml 0 19 0 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In Vivo Experiments</italic>
###xml 44 48 <span type="species:ncbi:10090">mice</span>
In Vivo Experiments-Female 9-week-old FVB/N mice (20-26 g each) were purchased from Taconic. All experiments were approved by the IACUC of Elan Pharmaceuticals and conducted in accordance with its guidelines. Drug administration was by intravenous tail vein injection with one 30 mg/kg dose of BI2536 or vehicle at a 5 ml/kg dose volume in 0.9% saline. Animals were euthanized by carbon dioxide 3 h after dosing. Brains were removed, rinsed in 0.9% saline, and separated into left and right hemispheres. The cortex was dissected from the right hemisphere, frozen on dry ice, and kept at -80 degreesC until used for quantitation of alpha-synuclein levels.
###end p 21
###begin p 22
###xml 0 11 0 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELISA Assay</italic>
###xml 528 530 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
ELISA Assay-Protein concentration of lysates was measured using the Micro BCA Kit (Pierce Biotechnology). Total alpha-synuclein and p-Ser-129 alpha-synuclein levels were each normalized to the total protein measured in each lysate, and a ratio of phosphorylated synuclein to total synuclein was calculated. Total and p-Ser-129 alpha-synuclein levels were quantified by sandwich ELISA using 1H7 as the capture antibody and biotinylated 5C12 or biotinylated 11A5 as the total or phosphosynuclein reporter antibodies as described (11) with the exception that cells were lysed in CEB instead of guanidine, and Costar EIA/RIA high binding 96-well plates (Corning) were used.
###end p 22
###begin p 23
###xml 0 58 0 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">qRT-PCR Analysis of PLK2 Knock-out Mouse Cortical Cultures</italic>
###xml 425 426 425 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 467 468 467 468 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 518 519 518 519 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 35 40 <span type="species:ncbi:10090">Mouse</span>
###xml 69 74 <span type="species:ncbi:10090">mouse</span>
###xml 300 305 <span type="species:ncbi:10090">mouse</span>
qRT-PCR Analysis of PLK2 Knock-out Mouse Cortical Cultures-cDNA from mouse cortical culture RNA was made using the SuperScript II first-strand synthesis system from Invitrogen. Gene expression assays from Applied Biosystems containing fluorogenic quantitative PCR primer/probe sets were obtained for mouse PLK2. Each cDNA was added to the qPCR master mix containing Applied Biosystems TaqMan universal PCR master with uracil N-glycosylase and ROX reference dye, 900 nm each of the forward and reverse primer, and 200 nm of the fluorogenic probe. qRT-PCR was carried out using one cycle of 50 degreesC, 2 min, 95 degreesC, 2 min and 40 cycles of 95 degreesC, 15 s and 60 degreesC, 1 min. For each well, the relative copy number of the gene of interest was normalized to total RNA as measured by the RiboGreen 96-well kit (Invitrogen).
###end p 23
###begin title 24
RESULTS
###end title 24
###begin p 25
###xml 410 412 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
###xml 678 680 666 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
###xml 682 684 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref28">28</xref>
To identify potential alpha-synuclein kinases, we screened HEK293 cells overexpressing alpha-synuclein for reduction of the p-Ser-129 modification, using the Ambion Silencer kinase siRNA library (Applied Biosystems). Such knockdown approaches have the advantage of avoiding artificial activity resulting from overexpression. Several kinases whose reduction decreased synuclein phosphorylation were identified (26). Of the candidate kinases, PLK2 was of particular interest because the siRNAs against this enzyme provided the largest and most consistent decrease in alpha-synuclein phosphorylation. Importantly, PLK2, as well as the closely related PLK3, are expressed in brain (27, 28).
###end p 25
###begin p 26
###xml 0 41 0 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLK Family Members Directly Phosphorylate</italic>
###xml 47 57 43 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-Synuclein</italic>
###xml 148 156 140 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 300 302 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 435 437 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 562 563 546 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 556 563 540 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 631 632 615 616 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 675 676 659 660 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 688 693 672 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pS129</italic>
###xml 711 712 695 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 705 712 689 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 712 719 696 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">, inset</italic>
PLK Family Members Directly Phosphorylate alpha-Synuclein-To confirm that PLK2 can directly phosphorylate alpha-synuclein, we examined the proteins in vitro. PLK2 was compared with the other members of the PLK family, as well as CK2, which has been previously shown to phosphorylate alpha-synuclein (10). Phosphorylation at Ser-129 was measured with a fluorescence assay using an antibody specific for phosphorylation at this residue (11); no other phosphorylation was observed by mass spectroscopy. PLK2 and -3 efficiently phosphorylated alpha-synuclein (Fig. 1A), with results consistent with complete phosphorylation of the 33 nm synuclein substrate (compare with the 33 nm p-Ser-129 (pS129) standard, Fig. 1A, inset). PLK1 had lower activity, comparable with that of CK2. To ensure that all enzymes were active, their abilities to phosphorylate another substrate, casein, were verified (supplemental Fig. S1). PLK4 had no measurable activity against either substrate but was able to autophosphorylate, suggesting that both casein and synuclein may be poor substrates for this enzyme.
###end p 26
###begin p 27
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 1.</label>
###xml 9 60 9 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Phosphorylation of &#945;-synuclein Ser-129 by PLK2.</bold>
###xml 60 61 56 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 419 428 369 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A/D ratio</italic>
###xml 489 494 439 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Inset</italic>
###xml 536 541 486 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pS129</italic>
###xml 563 564 513 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 569 570 519 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 596 597 546 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 630 631 576 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 698 705 644 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Control</italic>
###xml 846 849 788 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MOI</italic>
###xml 865 866 807 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 880 881 822 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 914 919 856 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink">copy#</italic>
###xml 9 1121 9 1059 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="28"><bold>Phosphorylation of &#945;-synuclein Ser-129 by PLK2.</bold><italic>A</italic>, phosphorylation of a biotinylated &#945;-synuclein substrate by recombinant PLK1 (&#9642;), PLK2 (&#8226;), PLK3 (&#8900;), PLK4 (&#9633;), and CK2 (&#9675;). Phosphorylation of the substrate at Ser-129 was measured using a phosphorylation-specific antibody with the kinase assay described under &#8220;Experimental Procedures.&#8221; Acceptor/donor ratio (<italic>A/D ratio</italic>) is a ratio of acceptor and donor fluorescence intensities. <italic>Inset</italic>, acceptor/donor ratios of the p-Ser-129 (<italic>pS129</italic>) synuclein standard. <italic>B</italic> and <italic>C</italic>, reduction of PLK2 mRNA (<italic>B</italic>) and p-Ser-129 &#945;-synuclein (<italic>C</italic>) by lentiviral constructs either containing a scrambled sequence (<italic>Control</italic>) or expressing PLK2 shRNA, in human cortical cultures overexpressing &#945;-synuclein (E46K mutant). The relative multiplicity of infection (<italic>MOI</italic>) is shown. **, <italic>p</italic> &lt; 0.01; ***, <italic>p</italic> &lt; 0.001. Relative copy numbers (<italic>copy#</italic>) of PLK2 mRNA were determined by qPCR (&#8220;Experimental Procedures&#8221;) and normalized to glyceraldehyde-3-phosphate dehydrogenase mRNA. Ratios of p-Ser-129 to total &#945;-synuclein were determined by ELISA.</p>
###xml 9 1121 9 1059 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="28"><bold>Phosphorylation of &#945;-synuclein Ser-129 by PLK2.</bold><italic>A</italic>, phosphorylation of a biotinylated &#945;-synuclein substrate by recombinant PLK1 (&#9642;), PLK2 (&#8226;), PLK3 (&#8900;), PLK4 (&#9633;), and CK2 (&#9675;). Phosphorylation of the substrate at Ser-129 was measured using a phosphorylation-specific antibody with the kinase assay described under &#8220;Experimental Procedures.&#8221; Acceptor/donor ratio (<italic>A/D ratio</italic>) is a ratio of acceptor and donor fluorescence intensities. <italic>Inset</italic>, acceptor/donor ratios of the p-Ser-129 (<italic>pS129</italic>) synuclein standard. <italic>B</italic> and <italic>C</italic>, reduction of PLK2 mRNA (<italic>B</italic>) and p-Ser-129 &#945;-synuclein (<italic>C</italic>) by lentiviral constructs either containing a scrambled sequence (<italic>Control</italic>) or expressing PLK2 shRNA, in human cortical cultures overexpressing &#945;-synuclein (E46K mutant). The relative multiplicity of infection (<italic>MOI</italic>) is shown. **, <italic>p</italic> &lt; 0.01; ***, <italic>p</italic> &lt; 0.001. Relative copy numbers (<italic>copy#</italic>) of PLK2 mRNA were determined by qPCR (&#8220;Experimental Procedures&#8221;) and normalized to glyceraldehyde-3-phosphate dehydrogenase mRNA. Ratios of p-Ser-129 to total &#945;-synuclein were determined by ELISA.</p></caption>
###xml 1121 1121 1059 1059 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0040963250001"/>
###xml 0 1121 0 1059 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig1"><label>FIGURE 1.</label><caption><p textid="28"><bold>Phosphorylation of &#945;-synuclein Ser-129 by PLK2.</bold><italic>A</italic>, phosphorylation of a biotinylated &#945;-synuclein substrate by recombinant PLK1 (&#9642;), PLK2 (&#8226;), PLK3 (&#8900;), PLK4 (&#9633;), and CK2 (&#9675;). Phosphorylation of the substrate at Ser-129 was measured using a phosphorylation-specific antibody with the kinase assay described under &#8220;Experimental Procedures.&#8221; Acceptor/donor ratio (<italic>A/D ratio</italic>) is a ratio of acceptor and donor fluorescence intensities. <italic>Inset</italic>, acceptor/donor ratios of the p-Ser-129 (<italic>pS129</italic>) synuclein standard. <italic>B</italic> and <italic>C</italic>, reduction of PLK2 mRNA (<italic>B</italic>) and p-Ser-129 &#945;-synuclein (<italic>C</italic>) by lentiviral constructs either containing a scrambled sequence (<italic>Control</italic>) or expressing PLK2 shRNA, in human cortical cultures overexpressing &#945;-synuclein (E46K mutant). The relative multiplicity of infection (<italic>MOI</italic>) is shown. **, <italic>p</italic> &lt; 0.01; ***, <italic>p</italic> &lt; 0.001. Relative copy numbers (<italic>copy#</italic>) of PLK2 mRNA were determined by qPCR (&#8220;Experimental Procedures&#8221;) and normalized to glyceraldehyde-3-phosphate dehydrogenase mRNA. Ratios of p-Ser-129 to total &#945;-synuclein were determined by ELISA.</p></caption><graphic xlink:href="zbc0040963250001"/></fig>
###xml 736 741 <span type="species:ncbi:9606">human</span>
FIGURE 1.Phosphorylation of alpha-synuclein Ser-129 by PLK2.A, phosphorylation of a biotinylated alpha-synuclein substrate by recombinant PLK1 (blacksquare, square, filled), PLK2 (*), PLK3 (open diamond), PLK4 (square), and CK2 (o). Phosphorylation of the substrate at Ser-129 was measured using a phosphorylation-specific antibody with the kinase assay described under "Experimental Procedures." Acceptor/donor ratio (A/D ratio) is a ratio of acceptor and donor fluorescence intensities. Inset, acceptor/donor ratios of the p-Ser-129 (pS129) synuclein standard. B and C, reduction of PLK2 mRNA (B) and p-Ser-129 alpha-synuclein (C) by lentiviral constructs either containing a scrambled sequence (Control) or expressing PLK2 shRNA, in human cortical cultures overexpressing alpha-synuclein (E46K mutant). The relative multiplicity of infection (MOI) is shown. **, p < 0.01; ***, p < 0.001. Relative copy numbers (copy#) of PLK2 mRNA were determined by qPCR ("Experimental Procedures") and normalized to glyceraldehyde-3-phosphate dehydrogenase mRNA. Ratios of p-Ser-129 to total alpha-synuclein were determined by ELISA.
###end p 27
###begin p 28
###xml 0 51 0 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Phosphorylation of &#945;-synuclein Ser-129 by PLK2.</bold>
###xml 51 52 47 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 410 419 360 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A/D ratio</italic>
###xml 480 485 430 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Inset</italic>
###xml 527 532 477 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pS129</italic>
###xml 554 555 504 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 560 561 510 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 587 588 537 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 621 622 567 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 689 696 635 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Control</italic>
###xml 837 840 779 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MOI</italic>
###xml 856 857 798 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 871 872 813 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 905 910 847 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">copy#</italic>
###xml 727 732 <span type="species:ncbi:9606">human</span>
Phosphorylation of alpha-synuclein Ser-129 by PLK2.A, phosphorylation of a biotinylated alpha-synuclein substrate by recombinant PLK1 (blacksquare, square, filled), PLK2 (*), PLK3 (open diamond), PLK4 (square), and CK2 (o). Phosphorylation of the substrate at Ser-129 was measured using a phosphorylation-specific antibody with the kinase assay described under "Experimental Procedures." Acceptor/donor ratio (A/D ratio) is a ratio of acceptor and donor fluorescence intensities. Inset, acceptor/donor ratios of the p-Ser-129 (pS129) synuclein standard. B and C, reduction of PLK2 mRNA (B) and p-Ser-129 alpha-synuclein (C) by lentiviral constructs either containing a scrambled sequence (Control) or expressing PLK2 shRNA, in human cortical cultures overexpressing alpha-synuclein (E46K mutant). The relative multiplicity of infection (MOI) is shown. **, p < 0.01; ***, p < 0.001. Relative copy numbers (copy#) of PLK2 mRNA were determined by qPCR ("Experimental Procedures") and normalized to glyceraldehyde-3-phosphate dehydrogenase mRNA. Ratios of p-Ser-129 to total alpha-synuclein were determined by ELISA.
###end p 28
###begin p 29
###xml 0 41 0 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Inhibition or Reduction of PLK2 Decreases</italic>
###xml 47 73 43 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-Synuclein Phosphorylation</italic>
###xml 254 255 250 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 260 261 256 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 246 261 242 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, <italic>B</italic> and <italic>C</italic></xref>
###xml 158 163 <span type="species:ncbi:9606">human</span>
Inhibition or Reduction of PLK2 Decreases alpha-Synuclein Phosphorylation-To establish the role of PLK2 in neurons, the effect of knockdown of PLK2 levels in human cortical cultures was investigated using shRNA in lentiviral vectors. As shown in Fig. 1, B and C, transduction with the PLK2 shRNA vectors caused substantial reduction of PLK2 message levels (by as much as 64%) and a parallel reduction of p-Ser-129 alpha-synuclein (as much as 78%). No effect was observed on PLK3 mRNA or total alpha-synuclein levels, and there was no cellular toxicity detected by Alamar Blue assay, suggesting that the effect on phospho-alpha-synuclein was mediated by specific mRNA silencing (data not shown).
###end p 29
###begin p 30
###xml 356 358 348 350 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 371 372 362 363 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 439 440 430 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 445 446 436 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 431 446 422 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, <italic>A</italic> and <italic>B</italic></xref>
###xml 464 465 455 456 <bold xmlns:xlink="http://www.w3.org/1999/xlink">3</bold>
###xml 477 483 468 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 485 487 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref29">29</xref>
###xml 699 700 686 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 693 700 680 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 838 840 821 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref30">30</xref>
###xml 1000 1002 979 981 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 1033 1034 1012 1013 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 75 80 <span type="species:ncbi:10090">mouse</span>
###xml 321 326 <span type="species:ncbi:10090">mouse</span>
###xml 610 615 <span type="species:ncbi:10090">mouse</span>
We have compared the potency of selected kinase inhibitors against PLK2 in mouse primary cortical cultures with their potency in the biochemical PLK2 assay. Many of the studies investigating CK2 as an alpha-synuclein kinase have used the inhibitor DMAT. We also find that DMAT inhibits alpha-synuclein phosphorylation in mouse cortical cultures, with an EC50 around 30 mum. However, it also inhibits PLK2 in the biochemical assay (Fig. 2, A and B). APMU (compound 3 in Johnson et al. (29)), which has good activity against PLK2 and -3 but is inactive against PLK1, inhibited alpha-synuclein phosphorylation in mouse cortical cultures. These results, together with the lower activity for PLK1 (Fig. 1A), suggest a limited role, if any, for PLK1 as an alpha-synuclein kinase. BI2536 has high potency and specificity for PLK family kinases (30) (see profiling results in supplemental Table S1). This compound inhibited up to 85-90% of alpha-synuclein phosphorylation in the cortical cultures, with an EC50 in multiple assays of 50-100 nm.
###end p 30
###begin p 31
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 2.</label>
###xml 9 70 9 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Reduction of p-Ser-129 &#945;-synuclein by inhibition of PLK2.</bold>
###xml 70 73 66 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#8211;D</italic>
###xml 221 229 177 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 244 245 200 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 276 277 232 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 354 355 310 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 381 382 337 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 438 446 390 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 461 462 413 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 477 480 429 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B&#8211;D</italic>
###xml 9 566 9 518 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32"><bold>Reduction of p-Ser-129 &#945;-synuclein by inhibition of PLK2.</bold><italic>A&#8211;D</italic>, inhibition of &#945;-synuclein phosphorylation by BI2536 (&#9642;), AMPU (&#9653;), or DMAT (&#8226;) by recombinant PLK2 in the <italic>in vitro</italic> kinase assay (<italic>A</italic>), in mouse cortical cultures (<italic>B</italic>), and in HEK293 cells by endogenous kinase (transfected with empty vector) (<italic>C</italic>) or by transfected PLK2 (<italic>D</italic>). Levels of p-Ser-129 &#945;-synuclein were measured by <italic>in vitro</italic> kinase assay (<italic>A</italic>) or by ELISA (<italic>B&#8211;D</italic>); the percentage of inhibition relative to controls with DMSO vehicle alone is shown.</p>
###xml 9 566 9 518 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="32"><bold>Reduction of p-Ser-129 &#945;-synuclein by inhibition of PLK2.</bold><italic>A&#8211;D</italic>, inhibition of &#945;-synuclein phosphorylation by BI2536 (&#9642;), AMPU (&#9653;), or DMAT (&#8226;) by recombinant PLK2 in the <italic>in vitro</italic> kinase assay (<italic>A</italic>), in mouse cortical cultures (<italic>B</italic>), and in HEK293 cells by endogenous kinase (transfected with empty vector) (<italic>C</italic>) or by transfected PLK2 (<italic>D</italic>). Levels of p-Ser-129 &#945;-synuclein were measured by <italic>in vitro</italic> kinase assay (<italic>A</italic>) or by ELISA (<italic>B&#8211;D</italic>); the percentage of inhibition relative to controls with DMSO vehicle alone is shown.</p></caption>
###xml 566 566 518 518 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0040963250002"/>
###xml 0 566 0 518 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig2"><label>FIGURE 2.</label><caption><p textid="32"><bold>Reduction of p-Ser-129 &#945;-synuclein by inhibition of PLK2.</bold><italic>A&#8211;D</italic>, inhibition of &#945;-synuclein phosphorylation by BI2536 (&#9642;), AMPU (&#9653;), or DMAT (&#8226;) by recombinant PLK2 in the <italic>in vitro</italic> kinase assay (<italic>A</italic>), in mouse cortical cultures (<italic>B</italic>), and in HEK293 cells by endogenous kinase (transfected with empty vector) (<italic>C</italic>) or by transfected PLK2 (<italic>D</italic>). Levels of p-Ser-129 &#945;-synuclein were measured by <italic>in vitro</italic> kinase assay (<italic>A</italic>) or by ELISA (<italic>B&#8211;D</italic>); the percentage of inhibition relative to controls with DMSO vehicle alone is shown.</p></caption><graphic xlink:href="zbc0040963250002"/></fig>
###xml 251 256 <span type="species:ncbi:10090">mouse</span>
FIGURE 2.Reduction of p-Ser-129 alpha-synuclein by inhibition of PLK2.A-D, inhibition of alpha-synuclein phosphorylation by BI2536 (blacksquare, square, filled), AMPU (triangle up), or DMAT (*) by recombinant PLK2 in the in vitro kinase assay (A), in mouse cortical cultures (B), and in HEK293 cells by endogenous kinase (transfected with empty vector) (C) or by transfected PLK2 (D). Levels of p-Ser-129 alpha-synuclein were measured by in vitro kinase assay (A) or by ELISA (B-D); the percentage of inhibition relative to controls with DMSO vehicle alone is shown.
###end p 31
###begin p 32
###xml 0 61 0 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Reduction of p-Ser-129 &#945;-synuclein by inhibition of PLK2.</bold>
###xml 61 64 57 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#8211;D</italic>
###xml 212 220 168 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 235 236 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 267 268 223 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 345 346 301 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 372 373 328 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 429 437 381 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 452 453 404 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 468 471 420 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B&#8211;D</italic>
###xml 242 247 <span type="species:ncbi:10090">mouse</span>
Reduction of p-Ser-129 alpha-synuclein by inhibition of PLK2.A-D, inhibition of alpha-synuclein phosphorylation by BI2536 (blacksquare, square, filled), AMPU (triangle up), or DMAT (*) by recombinant PLK2 in the in vitro kinase assay (A), in mouse cortical cultures (B), and in HEK293 cells by endogenous kinase (transfected with empty vector) (C) or by transfected PLK2 (D). Levels of p-Ser-129 alpha-synuclein were measured by in vitro kinase assay (A) or by ELISA (B-D); the percentage of inhibition relative to controls with DMSO vehicle alone is shown.
###end p 32
###begin p 33
###xml 55 63 55 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 237 238 237 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 231 238 231 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>C</italic></xref>
###xml 308 309 308 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 302 309 302 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>D</italic></xref>
Because comparison of inhibitor potencies in cells and in vitro can be complicated by the ability of cells to exclude or accumulate different inhibitors, we compared the potency of inhibitors in HEK293 cells transfected with PLK2 (Fig. 2C) or with vector controls (endogenous HEK293 cell kinases only, Fig. 2D). Transfection with PLK2 increases the levels of synuclein phosphorylation over 10-fold so that almost all of the activity could be attributed to the transfected kinase. Good agreement was observed between inhibitor potencies in the presence and absence of overexpressed PLK2. In the absence of kinase transfection, the maximum inhibition of p-Ser-129 alpha-synuclein was around 60%. The remainder may be due to an additional kinase in these cells.
###end p 33
###begin p 34
###xml 94 101 90 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 290 291 282 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 284 291 276 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 103 107 <span type="species:ncbi:10090">Mice</span>
BI2536 was used to validate the role of PLK family members in alpha-synuclein phosphorylation in vivo. Mice were dosed intravenously with BI2536, the brains were collected, and the levels of total and p-Ser-129 alpha-synuclein in cortical extracts were measured by ELISA. As shown in Fig. 3A, consistent and significant inhibition of alpha-synuclein phosphorylation was observed.
###end p 34
###begin p 35
###xml 29 33 29 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">plk2</italic>
###xml 215 219 211 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">plk2</italic>
###xml 219 222 215 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 630 631 610 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 636 637 616 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 622 637 602 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, <italic>B</italic> and <italic>C</italic></xref>
###xml 108 112 <span type="species:ncbi:10090">mice</span>
###xml 168 173 <span type="species:ncbi:10090">mouse</span>
The effect of removal of the plk2 gene on alpha-synuclein levels was also investigated using PLK2 knock-out mice. Primary cortical cultures from a homozygous knock-out mouse were compared with those from wild-type (plk2+/+) littermates. Measurement of mRNA levels by qRT-PCR showed that PLK2 expression was completely ablated. Comparison of alpha-synuclein and p-Ser-129 alpha-synuclein levels in primary cortical cultures from knock-out and wild-type littermates showed that alpha-synuclein phosphorylation was decreased by about 70%. A similar decrease was observed in soluble alpha-synuclein in 2-3-month-old cortices (Fig. 3, B and C).
###end p 35
###begin p 36
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 3.</label>
###xml 66 73 62 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 9 96 9 92 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Reduction of p-Ser-129 &#945;-synuclein by PLK inhibition <italic>in vivo</italic> and by PLK2 knock-out.</bold>
###xml 96 97 92 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 278 279 270 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 455 465 447 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">error bars</italic>
###xml 492 493 484 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 688 698 676 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">error bars</italic>
###xml 9 857 9 841 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="37"><bold>Reduction of p-Ser-129 &#945;-synuclein by PLK inhibition <italic>in vivo</italic> and by PLK2 knock-out.</bold><italic>A</italic>, mice were treated with either vehicle or 30 mg/kg of BI2536, eight mice per group. Levels of total and p-Ser-129 &#945;-synuclein were measured as under &#8220;Experimental Procedures.&#8221; <italic>B</italic>, cortical cultures were prepared from a PLK2 knock-out mouse (&#8211;/&#8211;) or a wild-type littermate control (+/+). Values shown are the means of triplicate cultures from each donor; <italic>error bars</italic> show standard deviations. <italic>C</italic>, fraction of &#945;-synuclein phosphorylated in cerebral cortices from a PLK2 knock-out (&#8211;/&#8211;) and two wild-type control (+/+) 2&#8211;3-month-old mice. Each bar represents results from a single brain; <italic>error bars</italic> represent standard deviation of assay replicates. Total &#945;-synuclein levels were not altered in either cortical cultures or intact brains (data not shown).</p>
###xml 9 857 9 841 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="37"><bold>Reduction of p-Ser-129 &#945;-synuclein by PLK inhibition <italic>in vivo</italic> and by PLK2 knock-out.</bold><italic>A</italic>, mice were treated with either vehicle or 30 mg/kg of BI2536, eight mice per group. Levels of total and p-Ser-129 &#945;-synuclein were measured as under &#8220;Experimental Procedures.&#8221; <italic>B</italic>, cortical cultures were prepared from a PLK2 knock-out mouse (&#8211;/&#8211;) or a wild-type littermate control (+/+). Values shown are the means of triplicate cultures from each donor; <italic>error bars</italic> show standard deviations. <italic>C</italic>, fraction of &#945;-synuclein phosphorylated in cerebral cortices from a PLK2 knock-out (&#8211;/&#8211;) and two wild-type control (+/+) 2&#8211;3-month-old mice. Each bar represents results from a single brain; <italic>error bars</italic> represent standard deviation of assay replicates. Total &#945;-synuclein levels were not altered in either cortical cultures or intact brains (data not shown).</p></caption>
###xml 857 857 841 841 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0040963250003"/>
###xml 0 857 0 841 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig3"><label>FIGURE 3.</label><caption><p textid="37"><bold>Reduction of p-Ser-129 &#945;-synuclein by PLK inhibition <italic>in vivo</italic> and by PLK2 knock-out.</bold><italic>A</italic>, mice were treated with either vehicle or 30 mg/kg of BI2536, eight mice per group. Levels of total and p-Ser-129 &#945;-synuclein were measured as under &#8220;Experimental Procedures.&#8221; <italic>B</italic>, cortical cultures were prepared from a PLK2 knock-out mouse (&#8211;/&#8211;) or a wild-type littermate control (+/+). Values shown are the means of triplicate cultures from each donor; <italic>error bars</italic> show standard deviations. <italic>C</italic>, fraction of &#945;-synuclein phosphorylated in cerebral cortices from a PLK2 knock-out (&#8211;/&#8211;) and two wild-type control (+/+) 2&#8211;3-month-old mice. Each bar represents results from a single brain; <italic>error bars</italic> represent standard deviation of assay replicates. Total &#945;-synuclein levels were not altered in either cortical cultures or intact brains (data not shown).</p></caption><graphic xlink:href="zbc0040963250003"/></fig>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
###xml 166 170 <span type="species:ncbi:10090">mice</span>
###xml 335 340 <span type="species:ncbi:10090">mouse</span>
###xml 633 637 <span type="species:ncbi:10090">mice</span>
FIGURE 3.Reduction of p-Ser-129 alpha-synuclein by PLK inhibition in vivo and by PLK2 knock-out.A, mice were treated with either vehicle or 30 mg/kg of BI2536, eight mice per group. Levels of total and p-Ser-129 alpha-synuclein were measured as under "Experimental Procedures." B, cortical cultures were prepared from a PLK2 knock-out mouse (-/-) or a wild-type littermate control (+/+). Values shown are the means of triplicate cultures from each donor; error bars show standard deviations. C, fraction of alpha-synuclein phosphorylated in cerebral cortices from a PLK2 knock-out (-/-) and two wild-type control (+/+) 2-3-month-old mice. Each bar represents results from a single brain; error bars represent standard deviation of assay replicates. Total alpha-synuclein levels were not altered in either cortical cultures or intact brains (data not shown).
###end p 36
###begin p 37
###xml 57 64 53 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 0 87 0 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Reduction of p-Ser-129 &#945;-synuclein by PLK inhibition <italic>in vivo</italic> and by PLK2 knock-out.</bold>
###xml 87 88 83 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 269 270 261 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 446 456 438 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">error bars</italic>
###xml 483 484 475 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 679 689 667 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">error bars</italic>
###xml 90 94 <span type="species:ncbi:10090">mice</span>
###xml 157 161 <span type="species:ncbi:10090">mice</span>
###xml 326 331 <span type="species:ncbi:10090">mouse</span>
###xml 624 628 <span type="species:ncbi:10090">mice</span>
Reduction of p-Ser-129 alpha-synuclein by PLK inhibition in vivo and by PLK2 knock-out.A, mice were treated with either vehicle or 30 mg/kg of BI2536, eight mice per group. Levels of total and p-Ser-129 alpha-synuclein were measured as under "Experimental Procedures." B, cortical cultures were prepared from a PLK2 knock-out mouse (-/-) or a wild-type littermate control (+/+). Values shown are the means of triplicate cultures from each donor; error bars show standard deviations. C, fraction of alpha-synuclein phosphorylated in cerebral cortices from a PLK2 knock-out (-/-) and two wild-type control (+/+) 2-3-month-old mice. Each bar represents results from a single brain; error bars represent standard deviation of assay replicates. Total alpha-synuclein levels were not altered in either cortical cultures or intact brains (data not shown).
###end p 37
###begin title 38
DISCUSSION
###end title 38
###begin p 39
###xml 133 141 129 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 451 455 439 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">plk2</italic>
###xml 380 385 <span type="species:ncbi:10090">mouse</span>
###xml 464 468 <span type="species:ncbi:10090">mice</span>
In this study, we have shown that members of the PLK family, specifically PLK1, -2, and -3, phosphorylate Ser-129 of alpha-synuclein in vitro, suggesting that they are capable of acting as direct alpha-synuclein kinases. Studies with inhibitors additionally suggest that PLK2 and PLK3 are responsible for the majority of alpha-synuclein phosphorylation in cultured neurons and in mouse brain. PLK2-specific shRNA knockdown and genetic deletion of the plk2 gene in mice identify a role for this kinase in particular.
###end p 39
###begin p 40
###xml 173 175 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
###xml 298 300 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref31">31</xref>
###xml 364 366 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref32">32</xref>
###xml 368 370 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref33">33</xref>
Previous studies of PLK2 have identified several properties that are particularly intriguing for an alpha-synuclein kinase. It is induced by excitotoxic glutamate agonists (27). Furthermore, Sheng and colleagues have proposed that PLK2 has a critical role in maintaining dendritic spine stability (31) and modulating excitatory glutaminergic synaptic connections (32, 33). Thus, the involvement of PLK2 in alpha-synuclein phosphorylation provides a potential link between excitotoxic responses and Lewy pathology. Investigation of how the biology of PLK2 relates to the pathogenesis of PD and DLB should help clarify the role of synuclein phosphorylation in these diseases.
###end p 40
###begin title 41
Supplementary Material
###end title 41
###begin title 42
[Supplemental Data]
###end title 42
###begin p 43
###xml 140 144 <span type="species:ncbi:10090">mice</span>
We thank Pearl Tang, Anna Liao, and Chris Nishioka for expert technical work; Seymond Pon and Melissa Monahan for managing and tracking the mice used in this study; Wes Zmolek, Eric Goldbach, and Heather Zhang for determining in vivo compound levels; Donald E. Walker for mass spectroscopic expertise; and Eugene M. Johnson, J. William Langston, and particularly Dale Schenk for support and helpful discussions.
###end p 43
###begin p 44
###xml 57 58 57 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 81 82 81 82 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 106 107 106 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 205 206 205 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
The abbreviations used are: PD, Parkinson disease; APMU, N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methylphenyl)urea; DLB, dementia with Lewy bodies; DMAT, 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole; CK2, casein kinase II; PLK, polo-like kinase; p-Ser-129, phospho-Ser-129; RT-PCR, reverse transcription-PCR; qRT-PCR, quantitative RT-PCR; ELISA, enzyme-linked immunosorbent assay; shRNA, short hairpin RNA; siRNA, small interfering RNA; CEB, cell extraction buffer; DMSO, dimethyl sulfoxide.
###end p 44

